With programs using both somatic cells and iPSCs, and an NK platform for oncology in the works, Japan's Healios aims to be a leader in regenerative medicine

blonca9
Nov 17, 2024
1 min read

CEO Hardy Kagimoto describes the company's programs, including how Multistem could soon be conditionally approved in Japan and is scheduled to enter a global phase 3 in ARDS. Plus, stroke, RPE tear AMD, and NK cells for solid tumors.

Recent Posts

See All

Corvus Pharma CEO Richard Miller fields follow-up questions about last week's atopic dermatitis data for the ITK inhibitor soquelitinib

SF Healthcare Week: Cytokinetics CEO Robert Blum discusses the approval and impending launch of the cardiomyopathy therapy MYQORZO

SF Healthcare Week: Sana Bio's CEO Steve Harr describes the science behind the company's cell therapy program that aims to be a cure for type 1 diabetes

With programs using both somatic cells and iPSCs, and an NK platform for oncology in the works, Japan's Healios aims to be a leader in regenerative medicine

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight